文献速递白血病

基于基因组DNA的可测量残留病监测在儿童急性髓系白血病中的未选择连续队列研究

Genomic DNA-based measurable residual disease monitoring in pediatric acute myeloid leukemia: unselected consecutive cohort study.
PubMed 文献 · Leukemia · 2023-11-24

该研究对133例连续诊断的儿童急性髓系白血病(AML)患者进行基因组DNA(gDNA)水平的可测量残留病(MRD)监测分析,在97%的患者中识别出可用作MRD靶标的(推测)原发遗传学异常,并对122例儿童进行了MRD监测;gDNA-based MRD在至少10⁻⁴灵敏度下对86%的患者可行,在5×10⁻⁴灵敏度下对次要异常或mRNA水平额外8%的患者可行,且在中/高危治疗组早期时间点显示独立预后价值。

要点

  • 在97%的儿童AML患者中识别出可用作MRD靶标的(推测)原发遗传学异常。
  • gDNA-based MRD监测在至少10⁻⁴灵敏度下对86%的患者可行,额外8%通过次要异常或mRNA水平实现。
  • gDNA-based MRD在中/高危治疗组早期时间点显示独立预后价值。

核心结论

  • 该研究证明gDNA-based MRD监测在儿童AML中具有广泛适用性、可行性和临床意义。

研究设计与样本

  • 未选择连续队列研究,纳入133例连续诊断的儿童AML患者,整合下一代测序于诊断流程,对122例儿童进行MRD监测。

主要发现

  • 在97%的患者中识别出(推测)原发遗传学异常作为MRD靶标。
  • gDNA-based MRD通过原发异常定量在至少10⁻⁴灵敏度下对86%的患者可行;通过5×10⁻⁴灵敏度下次要异常定量或mRNA水平对额外8%的患者可行。
  • gDNA-based MRD在中/高危治疗组早期时间点显示独立预后价值。

关键数值与推荐

  • gDNA-based MRD监测灵敏度至少10⁻⁴,对86%的患者可行;灵敏度5×10⁻⁴下次要异常或mRNA水平监测对额外8%的患者可行。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Measurable residual disease (MRD) monitoring in childhood acute myeloid leukemia (AML) is used to assess response to treatment and for early detection of imminent relapse. In childhood AML, MRD is typically evaluated using flow cytometry, or by quantitative detection of leukemia-specific aberrations at the mRNA level. Both methods, however, have significant limitations. Recently, we demonstrated the feasibility of MRD monitoring in selected subgroups of AML at the genomic DNA (gDNA) level. To evaluate the potential of gDNA-based MRD monitoring across all AML subtypes, we conducted a comprehensive analysis involving 133 consecutively diagnosed children. Integrating next-generation sequencing into the diagnostic process, we identified (presumed) primary genetic aberrations suitable as MRD targets in 97% of patients. We developed patient-specific quantification assays and monitored MRD in 122 children. The gDNA-based MRD monitoring via quantification of primary aberrations with a sensitivity of at least 10-4 was possible in 86% of patients; via quantification with sensitivity of 5 × 10-4, of secondary aberrations, or at the mRNA level in an additional 8%. Importantly, gDNA-based MRD exhibited independent prognostic value at early time-points in patients stratified to intermediate-/high-risk treatment arms. Our study demonstrates the broad applicability, feasibility, and clinical significance of gDNA-based MRD monitoring in childhood AML.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Zaliova M, Zuna J, Winkowska L, et al. Genomic DNA-based measurable residual disease monitoring in pediatric acute myeloid leukemia: unselected consecutive cohort study. Leukemia. 2023. PMID: 38001170. doi:10.1038/s41375-023-02083-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。